Episode Details
Back to EpisodesASCO26 Special: Assoc. Prof. Barata discusses ctDNA analysis from the KEYNOTE-564 trial
Published 1 week, 5 days ago
Description
In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Pedro Barata from Case Western Reserve University, Ohio (US). They discuss the results of the ctDNA analysis in participants with renal cell carcinoma (RCC) treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial and the potential impact of these results for clinical practice.
Read the abstract of this trial to know more.
For more updates on kidney cancer, please visit our educational platform UROONCO RCC.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.